Literature DB >> 20436505

Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation.

Sarah E Pinder1.   

Abstract

Ductal carcinoma in situ (DCIS) is a heterogeneous, unicentric precursor of invasive breast cancer, which is frequently identified through mammographic breast screening programs. The lesion can cause particular difficulties for specimen handling in the laboratory and typically requires even more diligent macroscopic assessment and sampling than invasive disease. Pitfalls and tips for macroscopic handling, microscopic diagnosis and assessment, including determination of prognostic factors, such as cytonuclear grade, presence or absence of necrosis, size of the lesion and distance to margins are described. All should be routinely included in histopathology reports of this disease; in order not to omit these clinically relevant details, synoptic reports, such as that produced by the College of American Pathologists are recommended. No biomarkers have been convincingly shown, and validated, to predict the behavior of DCIS till date.

Entities:  

Mesh:

Year:  2010        PMID: 20436505     DOI: 10.1038/modpathol.2010.40

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  28 in total

1.  Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy.

Authors:  José M A Moreira; Teresa Cabezón; Irina Gromova; Pavel Gromov; Vera Timmermans-Wielenga; Isidro Machado; Antonio Llombart-Bosch; Niels Kroman; Fritz Rank; Julio E Celis
Journal:  Mol Oncol       Date:  2010-10-08       Impact factor: 6.603

2.  Concordance of DNA methylation profiles between breast core biopsy and surgical excision specimens containing ductal carcinoma in situ (DCIS).

Authors:  Youdinghuan Chen; Jonathan D Marotti; Erik G Jenson; Tracy L Onega; Kevin C Johnson; Brock C Christensen
Journal:  Exp Mol Pathol       Date:  2017-07-12       Impact factor: 3.362

3.  Comparison of the underestimation rate in cases with ductal carcinoma in situ at ultrasound-guided core biopsy: 14-gauge automated core-needle biopsy vs 8- or 11-gauge vacuum-assisted biopsy.

Authors:  Y J Suh; M J Kim; E-K Kim; H J Moon; J Y Kwak; H R Koo; J H Yoon
Journal:  Br J Radiol       Date:  2012-03-14       Impact factor: 3.039

Review 4.  Intratumoral Heterogeneity in Ductal Carcinoma In Situ: Chaos and Consequence.

Authors:  Vidya C Sinha; Helen Piwnica-Worms
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-09-07       Impact factor: 2.673

Review 5.  Evolution of Premalignant Disease.

Authors:  Kit Curtius; Nicholas A Wright; Trevor A Graham
Journal:  Cold Spring Harb Perspect Med       Date:  2017-12-01       Impact factor: 6.915

6.  Impact of Histopathological Factors, Patient History and Therapeutic Variables on Recurrence-free Survival after Ductal Carcinoma in Situ: 8-Year Follow-up and Questionnaire Survey.

Authors:  M T van Mackelenbergh; C M Lindner; T Heilmann; I Alkatout; M Elessawy; C Mundhenke; N Maass; C Schem
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-01       Impact factor: 2.915

Review 7.  What is the malignant nature of human ductal carcinoma in situ?

Authors:  Virginia Espina; Lance A Liotta
Journal:  Nat Rev Cancer       Date:  2010-12-02       Impact factor: 60.716

8.  Large palpable ductal carcinoma in situ is Her-2 positive with high nuclear grade.

Authors:  Ahmad Monabati; Ali-Reza Sokouti; Sadat Noori Noori; Akbar Safaei; Abd-Rasul Talei; Shapoor Omidvari; Negar Azarpira
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

9.  Attacking breast cancer at the preinvasion stage by targeting autophagy.

Authors:  Virginia Espina; John Wysolmerski; Kirsten Edmiston; Lance A Liotta
Journal:  Womens Health (Lond)       Date:  2013-03

10.  Myoepithelial cell differentiation markers in ductal carcinoma in situ progression.

Authors:  Tanya D Russell; Sonali Jindal; Samiat Agunbiade; Dexiang Gao; Megan Troxell; Virginia F Borges; Pepper Schedin
Journal:  Am J Pathol       Date:  2015-09-04       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.